News Search Results
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 13, 2025, 06:00 ET ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
Therapeutics. About ReviR Therapeutics ReviR Therapeutics is a global biotechnology company committed to discovering and developing innovative therapies for patients with serious neurogenetic diseases worldwide. ReviR was founded
More news about: ReviR Therapeutics
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Oct 13, 2025, 05:30 ET Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Oct 13, 2025, 05:00 ET WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: WHO Foundation
Oct 13, 2025, 05:00 ET SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of
More news about: SystImmune, Inc.
Oct 12, 2025, 20:10 ET Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 10, 2025, 10:30 ET Single-use Bioprocessing Market worth US$33.67 billion by 2030 with 13.3% CAGR | MarketsandMarkets™.
announcements, including the expansion of its facilities in Germany, China, France, and Ireland, to increase the manufacturing capacity of its biotechnology products. Its expansion activities in Europe and the Asia Pacific in 2024 are further expected to strengthen its position in the single-use bioprocessing
More news about: MarketsandMarkets
Oct 10, 2025, 08:48 ET Development of the First Inner Ear Organoids by 3D Bioprinting for Pharmacological Screening in Hearing Disorders: CTIBIOTECH™ Announces Strategic Agreement With SATT AxLR and CILCARE
About CTIBIOTECH™ CTIBIOTECH™ is a biotechnology company specializing in the development of advanced human tissue models for research, drug discovery and cosmetic testing. Using state-of-the-art
More news about: CTIBIOTECH, CILCARE and SATT AXLR
Oct 10, 2025, 01:12 ET Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company
purchased or otherwise acquired aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025. aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
More news about: Robbins LLP
Oct 09, 2025, 18:56 ET Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
(omalizumab-igec) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Oct 09, 2025, 17:31 ET Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, among others.
More news about: DelveInsight Business Research, LLP
Oct 09, 2025, 14:00 ET WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed the previously announced definitive agreements
More news about: WallachBeth Capital LLC
Oct 09, 2025, 12:35 ET Rubin Rudman Partner Andrea Toulouse Named to Massachusetts Lawyers Weekly's Top Women of Law List
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Oct 09, 2025, 12:17 ET RegCell Scientific Founder and Board Member Dr. Shimon Sakaguchi Awarded Nobel Prize in Physiology or Medicine
EMERYVILLE, Calif., Oct. 9, 2025 /PRNewswire/ -- RegCell, Inc. a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the
More news about: RegCell, Inc.
Oct 09, 2025, 11:05 ET Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery
Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders
More news about: LifeSpan Vision Ventures
Oct 09, 2025, 11:05 ET Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery
Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology and longevity companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders
More news about: LifeSpan Vision Ventures
Oct 09, 2025, 10:10 ET Wearable Medical Devices Market Poised for USD 499.2 Billion by 2035, Growing at a CAGR 21.6% | Strategic Insights for CXOs and Healthcare Leaders
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 09, 2025, 10:00 ET FYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision Medicine
FYR, a biotechnology company leveraging extracellular vesicles (EVs) to create an end-to-end solution for new precision medicine tools, has selected Fuzzball, CIQ's
More news about: CIQ
Oct 09, 2025, 09:30 ET Stealth BioTherapeutics Announces Mito Assist™ Patient Support Program and Specialty Pharmacy Partnership with AnovoRx to Distribute FORZINITY™(elamipretide) injection
Oct. 9, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Oct 09, 2025, 08:42 ET American Liver Foundation Hosts National Legacy Gala Honoring Leaders in Liver Health
auction and dinner featuring a presentation to our award recipients who have made outstanding contributions to the liver community in the fields of biotechnology, medical innovation, and philanthropy. The 2025 Award Recipients include:
More news about: American Liver Foundation
Oct 09, 2025, 08:30 ET Policy Shifts Reshaping Pharma Strategy: IRA, PBM Reform and Beyond, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 09, 2025, 08:30 ET Can Neuroimaging Save Psychedelic Drug Development? Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 09, 2025, 08:30 ET Simplifying CRISPR Therapeutic Manufacturing: Practical Solutions to Accelerate and Simplify Manufacturing, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 09, 2025, 08:30 ET Pediatric Hematology-Oncology Trials: Successful Novel Therapeutic Strategies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks